RayKnowChina Research Map
Shortlist

Shandong First Medical University

山东第一医科大学

JinanUniversity or health system

Hospitals that carry this university's name, added together, plus papers and trials that name only the university.

Research activity, not treatment quality. Not medical advice. How this works

Nasopharyngeal carcinoma

鼻咽癌
0.5%Leads under 1 in 100 of China's research papers on NPC

Led 13 of 2,375 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (23.4%).

Run this PubMed search

Open trials led
2
Research papers it led
13
Trials it led
2
Share of China's trials
0.3%
Share of the world's papers
0.4%
Papers led per year
2021: 1120212022: 0020222023: 1120232024: 1120242025: 112025
ThemesImaging & AIRadiotherapy techniqueSide effects & quality of life

Hospitals counted here

  1. Shandong Cancer Hospital and Institute8
  2. Shandong Provincial Hospital Counted in the group total2
  3. Central Hospital Affiliated to Shandong First Medical University Counted in the group total1
  4. First Affiliated Hospital of Shandong First Medical University Counted in the group total1
  5. Second Affiliated Hospital of Shandong First Medical University Counted in the group total1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Oesophageal squamous cell carcinoma

食管鳞状细胞癌
3.6%Leads about 1 in 28 of China's research papers on ESCC

Led 104 of 2,923 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (6.9%).

Run this PubMed search

Open trials led
3
Research papers it led
104
Trials it led
10
Share of China's trials
1.8%
Share of the world's papers
2.4%
Papers led per year
2021: 0020212022: 2220222023: 1120232024: 2220242025: 002025
ThemesRadiotherapyNeoadjuvant & combined treatmentImaging & AI

Hospitals counted here

  1. Shandong Cancer Hospital and Institute65
  2. Shandong Provincial Hospital29
  3. First Affiliated Hospital of Shandong First Medical University6
  4. Central Hospital Affiliated to Shandong First Medical University4
  5. Binzhou People's Hospital, Shandong First Medical University1
  6. Second Affiliated Hospital of Shandong First Medical University Counted in the group total1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Concurrent chemoradiotherapyof different radiation doses and different irradiation fields for locally advanced thoracic esophageal squamous cell carcinoma: A randomized, multicenter, phase III clinical trial.2024Cancer communications (London, England)RCTFree full text
  2. Tislelizumab for consolidation therapy in patients with pathologically residual Esophageal Squamous Cell Carcinoma after definitive concurrent Chemoradiotherapy: a multicenter, randomized, controlled phase II trial.2024Future oncology (London, England)RCTFree full text
  3. Nimotuzumab plus concurrent chemo-radiotherapy in unresectable locally advanced oesophageal squamous cell carcinoma (ESCC): interim analysis from a Phase 3 clinical trial.2023British journal of cancerRCTFree full text
  4. Machine learning models predict overall survival and progression free survival of non-surgical esophageal cancer patients with chemoradiotherapy based on CT image radiomics signatures.2022Radiation oncology (London, England)RCTFree full text
  5. Comparison of concurrent chemoradiotherapy with radiotherapy alone for locally advanced esophageal squamous cell cancer in elderly patients: A randomized, multicenter, phase II clinical trial.2022International journal of cancerRCT
Trials on ClinicalTrials.gov6
  1. Neoadjuvant QL1706 Therapy for ESCCRecruitingNCT06908382Lead sponsorPhase 2Start 2025-04
  2. Evaluation of [18F]AlF-NOTA-PCP2 PET/CT for PD-L1 Detection in Malignant TumorsEnrolling by invitationNCT06690216Lead sponsorPhase 1/Phase 2Start 2024-03
  3. Efficacy and Safety of Tislelizumab Plus Chemotherapy as Conversion Therapy in Unresectable Locally Advanced ESCCRecruitingNCT07549100Lead sponsorStart 2023-05
  4. SKB500 Combinations in Patients With Esophageal Squamous Cell CarcinomaRecruitingNCT07700667Study sitePhase 2Start 2026-08
  5. A Clinical Trial of Ifinatamab Deruxtecan in People With Advanced Esophageal Cancer (MK-3475-06F)RecruitingNCT07405151Study sitePhase 1/Phase 2Start 2026-03
  6. A Phase II Clinical Study to Evaluate HLX43 in Patients With Recurrent/Metastatic ESCC Failed or Intolerance to Standard TherapyRecruitingNCT06769113Study sitePhase 2Start 2025-01

PubMed searchClinicalTrials.gov

Hepatocellular carcinoma

肝细胞癌
1.3%Leads about 1 in 78 of China's research papers on HCC

Led 191 of 14,765 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (5.5%).

Run this PubMed search

Open trials led
4
Research papers it led
191
Trials it led
13
Share of China's trials
0.9%
Share of the world's papers
0.7%
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 112025
ThemesRecurrence & prognosisLocal treatment (ablation, TACE, HAIC)Immunotherapy & targeted drugs
Papers it led5
  1. Targeting PYK2 with heterobifunctional T6BP helps mitigate MASLD and MASH-HCC progression.2025Journal of hepatology
  2. Targeting of GSDMD sensitizes HCC to anti-PD-1 by activating cGAS pathway and downregulating PD-L1 expression.2022Journal for immunotherapy of cancerFree full text
  3. Radiomic Model Based on Multisequence MRI to Preoperative Predict Ki-67 Expression in Hepatocellular Carcinoma.2026Academic radiology
  4. Predictive model development and validation of functional liver imaging score for prognosis of patients with hepatocellular carcinoma after surgical resection: a multicenter study.2026La Radiologia medica
  5. Hepatic arterial infusion chemotherapy combined with lenvatinib and programmed death receptor-1 inhibitors for hepatocellular carcinoma with Vp4 portal vein tumor thrombus: a multicenter, propensity score matching compar2026Hepatology international
Trials on ClinicalTrials.gov6
  1. Continuation of First-line Therapy With Radiotherapy Versus Early Switch to Second-line Therapy in Oligoprogressive HCCRecruitingNCT06841172Lead sponsorPhase 3Start 2025-07
  2. BITS-TO-HCC Study: HAIC+Iparomlimab/Tuvonralimab + Bevacizumab + Surgery/SBRT for BCLC-C HCC With PVTT and/or OligometastasesRecruitingNCT07062055Lead sponsorPhase 2Start 2025-07
  3. Sintilimab Combined With Stereotactic Body Radiotherapy as Neoadjuvant Therapy for Resectable HepatocellularNot yet recruitingNCT07352007Lead sponsorPhase 2Start 2025-12
  4. Efficacy and Safety of Sintilimab Combined With Lenvatinib and HAIC for Neoadjuvant Therapy of Borderline Resectable HCCRecruitingNCT06904014Lead sponsorPhase 2Start 2023-10
  5. First in Human Study of SIM0610 in Solid TumorsRecruitingNCT07348211Study sitePhase 1Start 2026-01
  6. MDN-001 Injection for the Treatment of Unresectable Primary Hepatocellular Carcinoma.RecruitingNCT07391839Study sitePhase 1Start 2025-08

PubMed searchClinicalTrials.gov

Stomach cancer

胃癌
1.6%Leads about 1 in 64 of China's research papers on Stomach cancer

Led 153 of 9,782 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (3.9%).

Run this PubMed search

Open trials led
1
Research papers it led
153
Trials it led
6
Share of China's trials
0.4%
Share of the world's papers
0.7%
Papers led per year
2021: 1120212022: 0020222023: 1120232024: 2220242025: 002025
ThemesImaging & AIImmunotherapy & targeted drugsPeritoneal spread & advanced disease

Over half of these papers are lab or animal studies.

Hospitals counted here

  1. Shandong Provincial Hospital59
  2. Shandong Cancer Hospital and Institute33
  3. Central Hospital Affiliated to Shandong First Medical University31
  4. First Affiliated Hospital of Shandong First Medical University26
  5. Third Affiliated Hospital of Shandong First Medical University2
  6. Second Affiliated Hospital of Shandong First Medical University2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Inetetamab combined with S-1 and oxaliplatin as first-line treatment for human epidermal growth factor receptor 2-positive gastric cancer.2024World journal of gastroenterologyRCTFree full text
  2. Effects of perioperative low-dose naloxone on the immune system in patients undergoing laparoscopic-assisted total gastrectomy: a randomized controlled trial.2024BMC anesthesiologyRCTFree full text
  3. Neoadjuvant chemoradiotherapy plus postoperative adjuvant XELOX chemotherapy versus postoperative adjuvant chemotherapy with XELOX regimen for local advanced gastric cancer-A randomized, controlled study.2021The British journal of radiologyRCTFree full text
  4. Potential Effects of FGFR4 in the Helicobacter pylori-Induced Inflammatory Carcinoma Transformation.2023Gastroenterology
  5. Simple Postoperative Markers for Early Identification of Low-Risk Patients After Gastric or Colorectal Cancer Surgery: A Retrospective Cohort Study.2026The American surgeon
Trials on ClinicalTrials.gov6
  1. Conversion Therapy Plus Surgery and Radiotherapy for Retroperitoneal Nodal Metastases in Gastric CancerRecruitingNCT07007182Lead sponsorPhase 2Start 2025-10
  2. Radical Surgery Versus Non-Surgery in Gastric Cancer Patients With Peritoneal Metastasis After Successful Conversion TherapyRecruitingNCT07789184Study sitePhase 3Start 2026-12
  3. Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.RecruitingNCT07385703Study sitePhase 3Start 2026-04
  4. Safety and Efficacy Evaluation of Single-Port Versus Multi-Port Robotic-Assisted Radical Distal Gastrectomy for Gastric CancerNot yet recruitingNCT07828899Study siteN/AStart 2026-10
  5. Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction CancerRecruitingNCT06731478Study sitePhase 3Start 2025-02
  6. An Artificial Intelligence Model for Aiding Claudin18.2 Expression Diagnosis in Gastric AdenocarcinomaEnrolling by invitationNCT07274579Study siteStart 2025-10

PubMed searchClinicalTrials.gov

Hepatoblastoma

肝母细胞瘤
2.6%Leads about 1 in 38 of China's research papers on Hepatoblastoma

Led 4 of 154 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (13.6%).

Run this PubMed search

Open trials led
0
Research papers it led
4
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.9%
Papers led per year
2021: 0020212022: 1120222023: 1120232024: 1120242025: 002025

Hospitals counted here

  1. Shandong Provincial Hospital3
  2. First Affiliated Hospital of Shandong First Medical University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Retinoblastoma

视网膜母细胞瘤
0.0%Leads none of China's research papers on Retinoblastoma

Led 0 of 301 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (12.0%).

Run this PubMed search

Open trials led
0
Research papers it led
0
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.0%
Trials on ClinicalTrials.gov1
  1. G-CSF Alone or Combination With GM-CSF on Prevention and Treatment of Infection in Children With Malignant TumorStatus unknownNCT02933333Study sitePhase 4Start 2016-09

PubMed searchClinicalTrials.gov

Osteosarcoma

骨肉瘤
0.9%Leads under 1 in 100 of China's research papers on Osteosarcoma

Led 20 of 2,257 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (4.3%).

Run this PubMed search

Open trials led
0
Research papers it led
20
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.4%
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 442025

Over half of these papers are lab or animal studies.

Hospitals counted here

  1. Shandong Provincial Hospital7
  2. Central Hospital Affiliated to Shandong First Medical University6
  3. First Affiliated Hospital of Shandong First Medical University3
  4. Affiliated Hospital of Shandong First Medical University1
  5. Zibo Central Hospital1
  6. Shangdong Provincial Hospital, Shandong First Medical University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Gastrointestinal stromal tumour

胃肠道间质瘤
1.0%Leads under 1 in 100 of China's research papers on Gastrointestinal stromal tumour ▼ from 2.1%

Led 5 of 523 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (6.3%).

Run this PubMed search

Open trials led
0
Research papers it led
5
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.3%
Papers led per year
2021: 3320212022: 1120222023: 0020232024: 1120242025: 002025

Hospitals counted here

  1. Shandong Provincial Hospital5

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Neuroblastoma

神经母细胞瘤
0.9%Leads under 1 in 100 of China's research papers on Neuroblastoma ▲ from 0.3%

Led 10 of 1,132 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (8.8%).

Run this PubMed search

Open trials led
0
Research papers it led
10
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.2%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 552025

Hospitals counted here

  1. Shandong Cancer Hospital and Institute4
  2. Shandong Provincial Hospital3
  3. First People's Hospital of Shandong First Medical University1
  4. Second Affiliated Hospital of School of Pharmaceutical Sciences of Shandong First Medical University1
  5. First Affiliated Hospital of Shandong First Medical University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Multiple myeloma

多发性骨髓瘤
0.9%Leads under 1 in 100 of China's research papers on Myeloma ▲ from 0.3%

Led 16 of 1,676 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (4.8%).

Run this PubMed search

Open trials led
0
Research papers it led
16
Trials it led
2
Share of China's trials
0.4%
Share of the world's papers
0.2%
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 2220242025: 222025
ThemesStem cell transplantDiagnosis, MRD & riskDrug combinations

Hospitals counted here

  1. Shandong Provincial Hospital6
  2. Shandong Cancer Hospital and Institute4
  3. First Affiliated Hospital of Shandong First Medical University2
  4. Second Affiliated Hospital of Shandong First Medical University Counted in the group total2
  5. Jinan People's Hospital, Shandong First Medical University Counted in the group total1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Multiple myeloma in a man with breast cancer: A case report and literature review.2025MedicineFree full text
  2. The Progress of Autologous Hematopoietic Stem Cell Transplantation in the Treatment of Multiple Myeloma (Review).2025Technology in cancer research & treatmentFree full text
  3. Whole-genome sequencing reveals cellular origin of concomitant chronic lymphocytic leukemia and multiple myeloma: a case report.2024Cancer biology & therapyFree full text
  4. Serum indicators in functional high-risk multiple myeloma patients undertaking proteasome inhibitors therapy: a retrospective study.2024Hematology (Amsterdam, Netherlands)
  5. An MRI-based radiomics nomogram for differentiating spinal metastases from multiple myeloma.2023Cancer imaging : the official publication of the International Cancer Imaging SocietyFree full text
Trials on ClinicalTrials.gov6
  1. Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple MyelomaNot yet recruitingNCT07569757Study sitePhase 3Start 2026-06
  2. A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple MyelomaRecruitingNCT07477587Study sitePhase 1Start 2026-05
  3. A Study of YKST02 in Participants With Relapsed or Refractory Multiple MyelomaRecruitingNCT06574568Study sitePhase 1Start 2024-06
  4. Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)RecruitingNCT06057402Study sitePhase 4Start 2023-10
  5. Mecapegfilgrastim With Chemotherapy for Peripheral Blood Stem Cell Mobilization in MM and LymphomaRecruitingNCT05294055Study sitePhase 2Start 2022-04
  6. A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other TreatmentsRecruitingNCT05020236Study sitePhase 3Start 2021-10

PubMed searchClinicalTrials.gov

B-cell acute lymphoblastic leukaemia (B-ALL)

B 细胞急性淋巴细胞白血病
0.9%Leads under 1 in 100 of China's research papers on B-ALL

Led 2 of 225 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (8.9%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.2%
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 112025
ThemesPhiladelphia chromosome & geneticsChildren

Hospitals counted here

  1. Shandong Provincial Hospital2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Aplastic anaemia

再生障碍性贫血
1.5%Leads about 1 in 68 of China's research papers on Aplastic anaemia ▲ from 0.8%

Led 6 of 412 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (17.2%).

Run this PubMed search

Open trials led
0
Research papers it led
6
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.4%
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 3320242025: 112025
ThemesChildrenStem cell transplantClonal evolution & PNH

Hospitals counted here

  1. Shandong Provincial Hospital4
  2. First Affiliated Hospital of Shandong First Medical University Counted in the group total1
  3. Shandong Cancer Hospital and Institute Counted in the group total1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Haemophilia A

血友病 A
1.1%Leads about 1 in 91 of China's research papers on Haemophilia A New since 2021

Led 3 of 272 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (15.8%).

Run this PubMed search

Open trials led
0
Research papers it led
3
Trials it led
1
Share of China's trials
1.2%
Share of the world's papers
0.1%
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 222025

Hospitals counted here

  1. First Affiliated Hospital of Shandong First Medical University2
  2. Central Hospital Affiliated to Shandong First Medical University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led3
  1. Application of enhanced recovery after surgery in total knee arthroplasty in patients with haemophilia A: A pilot study.2021Nursing openRCT
  2. Retrospective analysis of clinical data from 171 low-income patients with hemophilia in Shandong Province.2025Scientific reports
  3. Influencing factors of the outcome of patients with haemophilia after knee replacement-a retrospective study.2025BMC musculoskeletal disorders
Trials on ClinicalTrials.gov6
  1. To Evaluate the Clinical Study of GS1191-0445 Injection in the Treatment of Hemophilia ARecruitingNCT06833983Study sitePhase 3Start 2025-03
  2. An Open-label, Multicenter Phase I/II Clinical Trial to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetic/Pharmacodynamic (PK/PD) Characteristics of SR604 Injection in Patients With Hemophilia A/B and Congenital Factor VII DeficiencyRecruitingNCT07644832Study sitePhase 1/Phase 2Start 2024-05
  3. Neutrophil-to-lymphocyte and Platelet-to-lymphocyte Ratio in Predicting the Incidence of Nausea and VomitingStatus unknownNCT05636163Lead sponsorStart 2022-12
  4. Study of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein (FRSW107) as Prophylactic Treatment.Active, not recruitingNCT07684898Study sitePhase 3Start 2026-06
  5. Study of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein (FRSW107) On-Demand TreatmentActive, not recruitingNCT07663903Study sitePhase 3Start 2026-04
  6. Recombinant Single-chain Factor VIII (rVIII-SingleChain) in Chinese Participants With Hemophilia A Previously Treated With FVIII ProductsCompletedNCT06738485Study sitePhase 3Start 2025-01

PubMed searchClinicalTrials.gov

Fanconi anaemia

范可尼贫血
4.4%Leads about 1 in 23 of China's research papers on Fanconi anaemia New since 2021

Led 3 of 68 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (8.8%).

Run this PubMed search

Open trials led
0
Research papers it led
3
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.7%
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 2220242025: 002025

Hospitals counted here

  1. Shandong Provincial Hospital3

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Neuromyelitis optica spectrum disorder (NMOSD)

视神经脊髓炎谱系疾病
0.6%Leads under 1 in 100 of China's research papers on NMOSD

Led 3 of 485 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (10.5%).

Run this PubMed search

Open trials led
0
Research papers it led
3
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.2%
Papers led per year
2021: 0020212022: 1120222023: 1120232024: 1120242025: 002025
ThemesImagingRelapse preventionAntibodies & diagnosis

Hospitals counted here

  1. Shandong Provincial Hospital2
  2. Central Hospital Affiliated to Shandong First Medical University Counted in the group total1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Myasthenia gravis

重症肌无力
3.4%Leads about 1 in 29 of China's research papers on Myasthenia gravis ▼ from 5.0%

Led 17 of 499 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (6.6%).

Run this PubMed search

Open trials led
0
Research papers it led
17
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.8%
Papers led per year
2021: 0020212022: 2220222023: 1120232024: 1120242025: 112025
ThemesCrisis & intensive careAntibodies & diagnosisBiologic & complement drugs

Hospitals counted here

  1. First Affiliated Hospital of Shandong First Medical University11
  2. Shandong Provincial Hospital3
  3. Second Affiliated Hospital of Shandong First Medical University Counted in the group total1
  4. Provincial Hospital, Shandong First Medical University Counted in the group total1
  5. Shandong Cancer Hospital and Institute Counted in the group total1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Moyamoya disease

烟雾病
1.4%Leads about 1 in 71 of China's research papers on Moyamoya New since 2021

Led 5 of 356 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (19.9%).

Run this PubMed search

Open trials led
0
Research papers it led
5
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.4%
Papers led per year
2021: 0020212022: 0020222023: 3320232024: 1120242025: 112025
ThemesImaging & blood flowGeneticsRevascularisation surgery

Hospitals counted here

  1. First Affiliated Hospital of Shandong First Medical University3
  2. Shandong Provincial Hospital Counted in the group total1
  3. First People's Hospital of Shandong First Medical University Counted in the group total1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Wilson disease

肝豆状核变性(Wilson 病)
1.0%Leads about 1 in 100 of China's research papers on Wilson disease New since 2021

Led 2 of 201 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (7.5%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.3%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 2220242025: 002025
ThemesGenetics (ATP7B)Brain & movement symptomsTreatment (chelation, zinc)

Hospitals counted here

  1. Shandong Provincial Hospital2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Anti-NMDA receptor encephalitis

抗 NMDA 受体脑炎
4.9%Leads about 1 in 20 of China's research papers on Anti-NMDA receptor encephalitis ▲ from 3.2%

Led 13 of 264 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (10.2%).

Run this PubMed search

Open trials led
0
Research papers it led
13
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
1.8%
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 442025

Hospitals counted here

  1. Shandong Provincial Hospital8
  2. First Affiliated Hospital of Shandong First Medical University4
  3. Central Hospital Affiliated to Shandong First Medical University2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Takayasu arteritis

大动脉炎
1.1%Leads about 1 in 93 of China's research papers on Takayasu arteritis

Led 2 of 187 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (24.6%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.2%
Papers led per year
2021: 0020212022: 1120222023: 1120232024: 0020242025: 002025

Hospitals counted here

  1. First Affiliated Hospital of Shandong First Medical University1
  2. Shandong Provincial Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Idiopathic pulmonary fibrosis

特发性肺纤维化
0.5%Leads under 1 in 100 of China's research papers on Idiopathic pulmonary fibrosis

Led 5 of 989 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (4.3%).

Run this PubMed search

Open trials led
0
Research papers it led
5
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.1%
Papers led per year
2021: 2220212022: 0020222023: 0020232024: 0020242025: 332025

Hospitals counted here

  1. Shandong Provincial Hospital3
  2. Shandong Occupational Disease Hospital1
  3. Shandong Cancer Hospital and Institute1
  4. Medical University Affiliated Liaocheng Second Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Amyotrophic lateral sclerosis

肌萎缩侧索硬化症
0.4%Leads under 1 in 100 of China's research papers on Amyotrophic lateral sclerosis New since 2021

Led 3 of 779 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (8.3%).

Run this PubMed search

Open trials led
0
Research papers it led
3
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.05%
Papers led per year
2021: 1120212022: 0020222023: 1120232024: 0020242025: 112025

Hospitals counted here

  1. Shandong Provincial Hospital2
  2. First Affiliated Hospital of Shandong First Medical University2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Behçet disease

白塞病
1.2%Leads about 1 in 82 of China's research papers on Behçet disease New since 2021

Led 3 of 245 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (22.9%).

Run this PubMed search

Open trials led
0
Research papers it led
3
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.2%
Papers led per year
2021: 1120212022: 1120222023: 0020232024: 1120242025: 002025

Hospitals counted here

  1. Shandong Provincial Hospital2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

IgA nephropathy

IgA 肾病
0.5%Leads under 1 in 100 of China's research papers on IgA nephropathy

Led 4 of 736 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (9.4%).

Run this PubMed search

Open trials led
0
Research papers it led
4
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.2%
Papers led per year
2021: 1120212022: 2220222023: 0020232024: 0020242025: 112025

Hospitals counted here

  1. Shandong Provincial Hospital3
  2. First Affiliated Hospital of Shandong First Medical University1
  3. Provincial Hospital, Shandong First Medical University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Osteogenesis imperfecta

成骨不全症
7.1%Leads about 1 in 14 of China's research papers on Osteogenesis imperfecta ▲ from 1.5%

Led 7 of 99 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (17.2%).

Run this PubMed search

Open trials led
0
Research papers it led
7
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.9%
Papers led per year
2021: 0020212022: 2220222023: 0020232024: 2220242025: 112025

Hospitals counted here

  1. Shandong Provincial Hospital6
  2. First Affiliated Hospital of Shandong First Medical University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Primary biliary cholangitis

原发性胆汁性胆管炎
1.0%Leads about 1 in 100 of China's research papers on Primary biliary cholangitis

Led 3 of 300 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (12.0%).

Run this PubMed search

Open trials led
0
Research papers it led
3
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.3%
Papers led per year
2021: 0020212022: 1120222023: 1120232024: 0020242025: 112025

Hospitals counted here

  1. Shandong Provincial Hospital2
  2. Jinan People's Hospital, Shandong First Medical University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Hirschsprung disease

先天性巨结肠
1.9%Leads about 1 in 54 of China's research papers on Hirschsprung disease

Led 3 of 161 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (13.0%).

Run this PubMed search

Open trials led
0
Research papers it led
3
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.4%
Papers led per year
2021: 1120212022: 1120222023: 0020232024: 0020242025: 112025

Hospitals counted here

  1. Shandong Provincial Hospital3

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov